Persistence of HLA-DQ Antibodies in Transplant Patients Following Desensitization Treatment.

IF 0.7 4区 医学 Q4 TRANSPLANTATION
Begüm Yavaşcaoğlu Üney, Miray Kavuzlu, Caner İncekaş, Bilkay Baştürk, Atilla Sezgin, Mehmet Haberal
{"title":"Persistence of HLA-DQ Antibodies in Transplant Patients Following Desensitization Treatment.","authors":"Begüm Yavaşcaoğlu Üney, Miray Kavuzlu, Caner İncekaş, Bilkay Baştürk, Atilla Sezgin, Mehmet Haberal","doi":"10.6002/ect.2025.0094","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The functionality of the transplanted graft is considered the most important step in transplant. Both HLA tissue compatibility between recipients and donors and the presence of antibodies against the HLA structure in the recipient's serum play essential roles. The presence of these antibodies can be ascertained either before or after transplant. Although desen-sitization treatment provides the chance of transplant to immunized patients, it also prolongs graft survival in antibody-mediated rejection that develops after transplant. In this retrospective study, we aimed to determine treatment-related responses of anti-HLA antibodies in heart and renal transplant patients diagnosed with antibody-mediated rejection.</p><p><strong>Materials and methods: </strong>We evaluated 60 samples from 18 patients who were followed in our center for at least 4 years and who had treatment before and after desensitization (plasmapheresis, intravenous immunoglobulin, and/or rituximab). Serum samples of the patients were tested for panel reactive antibody screening class I and II (One Lambda, Inc) test by Luminex method and single antigen class I and/or II (One Lambda, Inc) results by Luminex method. Mean fluorescence intensity ≥1000 was considered positive. To determine the presence of donor-specific antibodies, HLA tissue group samples of donors were studied by high-resolution method.</p><p><strong>Results: </strong>Studied antibodies, particularly those with mean fluorescence intensity >10 000 against class II HLA-DQ, remained resistant to treatment.</p><p><strong>Conclusions: </strong>Our study results showed that the class II HLA-DQ tissue group and anti-HLA antibodies against it play an important role in reducing the need for desensitization therapy and maintaining graft tissue functionality.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"23 6","pages":"415-420"},"PeriodicalIF":0.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6002/ect.2025.0094","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: The functionality of the transplanted graft is considered the most important step in transplant. Both HLA tissue compatibility between recipients and donors and the presence of antibodies against the HLA structure in the recipient's serum play essential roles. The presence of these antibodies can be ascertained either before or after transplant. Although desen-sitization treatment provides the chance of transplant to immunized patients, it also prolongs graft survival in antibody-mediated rejection that develops after transplant. In this retrospective study, we aimed to determine treatment-related responses of anti-HLA antibodies in heart and renal transplant patients diagnosed with antibody-mediated rejection.

Materials and methods: We evaluated 60 samples from 18 patients who were followed in our center for at least 4 years and who had treatment before and after desensitization (plasmapheresis, intravenous immunoglobulin, and/or rituximab). Serum samples of the patients were tested for panel reactive antibody screening class I and II (One Lambda, Inc) test by Luminex method and single antigen class I and/or II (One Lambda, Inc) results by Luminex method. Mean fluorescence intensity ≥1000 was considered positive. To determine the presence of donor-specific antibodies, HLA tissue group samples of donors were studied by high-resolution method.

Results: Studied antibodies, particularly those with mean fluorescence intensity >10 000 against class II HLA-DQ, remained resistant to treatment.

Conclusions: Our study results showed that the class II HLA-DQ tissue group and anti-HLA antibodies against it play an important role in reducing the need for desensitization therapy and maintaining graft tissue functionality.

移植患者脱敏治疗后HLA-DQ抗体的持续存在。
目的:移植物的功能被认为是移植中最重要的一步。受体和供体之间的HLA组织相容性以及受体血清中针对HLA结构的抗体的存在都起着至关重要的作用。这些抗体的存在可以在移植前或移植后确定。虽然脱敏治疗为免疫患者提供了移植的机会,但它也延长了移植后抗体介导的排斥反应的存活时间。在这项回顾性研究中,我们旨在确定诊断为抗体介导排斥的心脏和肾脏移植患者的抗hla抗体的治疗相关反应。材料和方法:我们评估了来自18例患者的60份样本,这些患者在我们的中心随访了至少4年,并且在脱敏前后接受了治疗(血浆置换、静脉注射免疫球蛋白和/或利妥昔单抗)。采用Luminex方法对患者血清样本进行组反应性抗体筛选I类和II类(One Lambda, Inc)检测,采用Luminex方法对单抗原I类和/或II类(One Lambda, Inc)检测。平均荧光强度≥1000为阳性。为了确定供者特异性抗体的存在,采用高分辨率方法研究供者HLA组织组样本。结果:研究的抗体,特别是针对II类HLA-DQ的平均荧光强度为bbb10 000的抗体,对治疗仍有耐药性。结论:我们的研究结果表明,II类HLA-DQ组织组及其抗hla抗体在减少脱敏治疗的需要和维持移植物组织功能方面发挥着重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
11.10%
发文量
258
审稿时长
6-12 weeks
期刊介绍: The scope of the journal includes the following: Surgical techniques, innovations, and novelties; Immunobiology and immunosuppression; Clinical results; Complications; Infection; Malignancies; Organ donation; Organ and tissue procurement and preservation; Sociological and ethical issues; Xenotransplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信